



Photodynamic Therapy 2.0

Guest Editors:

Dr. Stefano Bacci

Research Unit of Histology and Embryology, Department of Biology, University of Florence, Florence, Italy

Prof. Dr. Kyungsu Kang

Principal Research Scientist, Natural Product Informatics Research Center, Korea Institute of Science and Technology (KIST), 679 Saimdang-ro, Gangneung 25451, Gangwon-do, Republic of Korea

Deadline for manuscript submissions:

closed (31 January 2024)

Message from the Guest Editors

Dear Colleagues,

Dedicating a volume to photodynamic therapy takes on great significance because it means that many steps have been taken to understand that such therapy can take on meaning. PDT is based on the cytotoxic action of some hyperactive oxygen species, especially singlet oxygen but also superoxide anion and hydroxyl radicals, generated by the transfer of energy and/or electrons from the photoexcited oxygen sensitizer. Three important mechanisms are responsible for the efficacy of PDT: (1) the direct death of tumor cells or inflammation, (2) damage to tumor vessels, and (3) immunological response associated with the stimulation of leukocytes and the release of interleukins and other cytokines, growth factors, complement components, acute-phase proteins and other immunoregulators.

After the first successful edition, we are now launching a second volume, "Photodynamic Therapy 2.0". This new Issue continues to cover all aspects of photodynamic therapy including the discovery of new natural and synthetic photosensitizers, biomaterials and nanotechnology, in vitro and in vivo studies and clinical trials.

Dr. Stefano Bacci
Prof. Dr. Kyungsu Kang
Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)